EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 9

Senna Senna alexandrina Mill.

Also called: Alexandrian senna, Tinnevelly senna, Cassia angustifolia Vahl (synonym), Cassia senna L. (synonym), Cassia acutifolia Delile (synonym)

Senna is a shrub whose leaves and pods contain sennosides, anthraquinone glycosides that act as a stimulant laxative. LiverTox notes it is available without prescription and used in many over-the-counter laxatives; it is also a dietary supplement ingredient.

Category
Botanical
Part used
Leaves and pods (fruits)
Strongest evidence
C Limited
Native range
Native from the Sahara and Sahel to the Indian Subcontinent (POWO: "Sahara & Sahel to Indian Subcontinent")
Reviewed
2026-10-29

Class 2 Moderately studied in people. A 2021 meta-analysis pooled 3 RCTs (318 children) comparing oral senna with polyethylene glycol for colonoscopy preparation; a 2023 meta-analysis pooled 2 RCTs of senna for chronic constipation in adults (source 4). [9]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied1 body area · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Senna does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Senna, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Chronic idiopathic constipation in adultsCIn one 28-day double-blind trial (90 patients across senna, magnesium oxide and placebo arms), overall improvement was 69.2% with senna 1.0 g versus 11.7% with placebo; bowel movements and quality of life improved. No severe adverse events. [3]
Chronic constipation in adults (pooled trials)CA 2023 meta-analysis pooling two senna trials found 61% responded versus 28% on control, a difference that was not statistically significant (RR 2.78, 95% CI 0.93–8.27). [4]
Constipation in palliative careCA Cochrane review of five small trials comparing laxatives, including senna, found similar effectiveness, with evidence too limited to rank them. [5]

Main constituents: Anthraquinone derivatives and their glucosides; colonic bacteria release the active forms rhein and rhein-anthrone [1]; Hydroxyanthracene derivatives, standardized and expressed as sennoside B [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Senna 1.0 g daily for 28 days (chronic constipation trial). [3]
  • EU monograph (2018), adolescents over 12 and adults: preparation equivalent to 10–30 mg hydroxyanthracene derivatives (as sennoside B) once daily at night, for no more than 1 week. [2]
  • LiverTox gives the typical dose as 15 to 30 mg of sennosides twice a day, recommending short-term use under one week. [1]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score D
    A: well known causeE: unlikely cause

    LiverTox likelihood score D (possible rare cause of clinically apparent liver injury), chapter updated April 1, 2020: rare hepatocellular injury …

    Details and sources
  • Pregnancy and breastfeeding
    Use during pregnancy is contraindicated (experimental data on a genotoxic risk of several anthranoids, e.g.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    3 listed

    Cardiac glycosides; Antiarrhythmics and QT-prolonging medicines; Diuretics and corticosteroids

    Details and sources
  • Cancer evaluations (IARC, NTP)
    1 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    See details

    FDA does not approve dietary supplements.

    Details and sources
  • Dose in official monographs
    Stated

    EU (HMPC, well-established use, EMA/HMPC/625849/2015, adopted 25 September 2018), adolescents over 12, adults and elderly: herbal preparation …

    Details and sources
  • Short-term use only: the EU monograph says not to use for more than 1 week, contraindicates use under 12 years and in pregnancy and breastfeeding, and advises avoiding long-term stimulant laxative use. [2]
  • Liver: LiverTox likelihood score D (possible rare cause of clinically apparent liver injury). Cases involved high doses over longer periods than recommended, with onset usually after 3 to 5 months; most were mild to moderate and resolved on stopping, but severe cases with acute liver failure are described. [1]
  • Overdose or abuse causes griping pain and severe diarrhea with fluid and electrolyte (potassium) loss. [2]
  • Chronic use may cause pseudomelanosis coli (usually recedes after stopping); long-term use may lead to water and electrolyte imbalance, albuminuria and hematuria; chronic overdoses of anthranoid-containing products may lead to toxic hepatitis. [2]
  • Senna pods, their extracts and several hydroxyanthracene derivatives were mutagenic and genotoxic in in vitro tests (not proven in vivo for senna); long-term carcinogenicity studies with senna pods reported effects on kidneys and colon/cecum. [2]
  • NTP found no evidence of carcinogenic activity of senna in a 40-week feed study in p53-deficient mice, but senna caused epithelial hyperplasia of the large intestine. [6]
  • Do not confuse with coffee senna (Cassia occidentalis), a different plant linked to severe toxicity with encephalopathy, muscle and liver damage, mainly in children in India. [1]
Interactions

Interactions

Senna
From the table below 3 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Senna
WithWhat happens
Cardiac glycosidesLow potassium from long-term laxative abuse potentiates the action of cardiac glycosides. [2]
Antiarrhythmics and QT-prolonging medicinesLow potassium from long-term laxative abuse interacts with antiarrhythmics; the EU monograph says people taking these or QT-prolonging medicines must consult a doctor before using senna leaf. [2]
Diuretics, corticosteroids and licorice rootConcomitant use may enhance potassium loss (EU monograph). [2]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • EU monograph preparations are standardized to 10–30 mg hydroxyanthracene derivatives per dose, calculated as sennoside B. [2]
Regulation

Regulatory status

  • EU: European Union herbal monograph (HMPC, well-established use; adopted 25 September 2018) for short-term use in occasional constipation. [2]
  • US: LiverTox states senna is available without prescription and is used in many over-the-counter laxatives in combination with other agents. [1]
  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; manufacturers and distributors have initial responsibility for their safety. [7]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Sennosides (hydroxyanthracene glycosides, expressed as sennoside B) Hydroxyanthracene (anthraquinone) glycosides [P1]
  • Rhein anthrone (active metabolite formed by colonic bacteria) Anthrone [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI list (dated July 9, 2026; checked 2026-10-29) has 2 notifications naming Cassia angustifolia (a synonym of Senna alexandrina): NDI 1005, submitted 2017-03-13, and NDI 1009, submitted 2017-03-14; FDA's response to both is dated 2017-05-12. The list gives the date of FDA's response letter but not what it said. [P2]
  • The same list has 1 notification naming calcium sennosides: NDI 787, submitted 2013-02-19, FDA response dated 2013-04-22. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • Senna (CASRN 8013-11-4), NTP GMM 15 (April 2012): no evidence of carcinogenic activity in male or female p53 haploinsufficient mice fed 100 to 10,000 ppm for 40 weeks; senna induced epithelial hyperplasia of the large intestine (colon and cecum). [P3]
  • No IARC evaluation of senna was found (IARC Monographs list of classifications checked 2026-10-29). [P4]
  • EU monograph: senna pods, their extracts and several hydroxyanthracene derivatives were mutagenic and genotoxic in several in vitro test systems, but for senna this was not proven in vivo; long-term carcinogenicity studies with senna pods reported effects on kidneys and colon/cecum. [P1]

Liver (NIH LiverTox)

  • LiverTox likelihood score D (possible rare cause of clinically apparent liver injury), chapter updated April 1, 2020: rare hepatocellular injury after high doses over 3 to 5 months, usually resolving after stopping; rechallenge caused recurrence. [P5]

Interactions with medicines

  • Cardiac glycosides: Hypokalemia from long-term laxative abuse potentiates their action (EU monograph). [P1]
  • Antiarrhythmics and QT-prolonging medicines: Hypokalemia from long-term laxative abuse interacts with antiarrhythmics; people taking these or QT-prolonging medicines must consult a doctor before using senna leaf (EU monograph). [P1]
  • Diuretics and corticosteroids: Concomitant use may enhance potassium loss (EU monograph). [P1]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • Licorice root: Concomitant use may enhance potassium loss (EU monograph). [P1]

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination of each dietary-ingredient component (21 CFR 111.75(a)(1)(i)) — Required by the US dietary supplement cGMP rule for any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P6]
  • Hydroxyanthracene derivatives assay, calculated as sennoside B — The EU monograph defines preparations by their hydroxyanthracene-derivative content (10–30 mg per dose as sennoside B). [P1]

Supply and conservation

  • IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29. [P7]

Absorption in people

  • Senna is minimally absorbed; colonic bacteria release the active forms, rhein and rhein-anthrone. [P5]
  • EU monograph: sennosides are not absorbed in the upper gut; 3-6% of metabolites are excreted in urine and about 90% of sennosides leave in feces as polymers. In human studies with senna pods powder (20 mg sennosides) for 7 days, blood rhein peaked at 100 ng/ml without accumulation. [P1]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU (HMPC, well-established use, EMA/HMPC/625849/2015, adopted 25 September 2018), adolescents over 12, adults and elderly: herbal preparation equivalent to 10–30 mg hydroxyanthracene derivatives (as sennoside B) once daily at night; not for more than 1 week; contraindicated under 12 years. [P1]

Pregnancy and breastfeeding

  • Use during pregnancy is contraindicated (experimental data on a genotoxic risk of several anthranoids, e.g. emodin and aloe-emodin) and during lactation (rhein passes into breast milk in small amounts) (EU herbal monograph, 2018). [P1]

Sources for this profile

  1. European Medicines Agency, HMPC. European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium, Revision 1 (EMA/HMPC/625849/2015; adopted 25 September 2018), 2018-09-25. ema.europa.eu
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. National Toxicology Program. NTP GMM 15: Toxicology Study of Senna in C57BL/6NTac Mice and Toxicology and Carcinogenesis Study of Senna in Genetically Modified C3B6.129F1/Tac-Trp53tm1Brd N12 Haploinsufficient Mice (Feed Studies), April 2012, 2012-04. ntp.niehs.nih.gov
  4. IARC Monographs. List of Classifications, Agents classified by the IARC Monographs, Volumes 1–142 (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  5. NIH LiverTox (NIDDK). Senna (Last Update: April 1, 2020), 2020-04-01. ncbi.nlm.nih.gov
  6. eCFR. 21 CFR 111.75 (Title 21 up to date as of 10/27/2026), 2026-10-27. ecfr.gov
  7. GBIF species API: IUCN Red List category for Senna alexandrina, 2026-10-29. api.gbif.org
Sources

Sources

  1. NIH LiverTox (NIDDK). Senna (Last Update: April 1, 2020), 2020-04-01. ncbi.nlm.nih.gov
  2. European Medicines Agency, HMPC. European Union herbal monograph on Senna alexandrina Mill. (Cassia senna L.; Cassia angustifolia Vahl), folium, Revision 1 (EMA/HMPC/625849/2015; adopted 25 September 2018), 2018-09-25. ema.europa.eu
  3. Morishita D, et al. Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. Am J Gastroenterol 2021 (PMID 32969946), 2021-01-01. pubmed.ncbi.nlm.nih.gov
  4. van der Schoot A, et al. The effect of food, vitamin, or mineral supplements on chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2023 (PMID 37243443), 2023-11. pubmed.ncbi.nlm.nih.gov
  5. Candy B, et al. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev 2015 (PMID 25967924), 2015-05-13. pubmed.ncbi.nlm.nih.gov
  6. National Toxicology Program. NTP Genetically Modified Model Report on the Toxicology Study of Senna (CASRN 8013-11-4) in C57BL/6NTac Mice and Toxicology and Carcinogenesis Study of Senna in Genetically Modified C3B6.129F1/Tac-Trp53tm1Brd N12 Haploinsufficient Mice (Feed Studies). NTP GMM 15, April 2012, 2012-04. ntp.niehs.nih.gov
  7. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  8. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data (Govaerts et al., Sci Data 2021). Senna alexandrina Mill. (accessed 2026-10-29); synonyms (Cassia angustifolia Vahl, Cassia senna L., Cassia acutifolia Delile) from WCVP, 2026-10-29. powo.science.kew.org
  9. Watanabe J, Kotani K. Polyethylene glycol versus senna for bowel preparation for colonoscopy in children: updated evidence by a systematic review and meta-analysis. Cureus 2021;13(9):e17813 (PMID 34660023), 2021-09-08. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.